Tolerability and Safety of Inhaled Colistimethate Sodium (CMS) Administered Once Daily Compared to Twice Daily Dosing in Adult and Adolescent Subjects with Cystic Fibrosis and Chronic Pseudomonas Aeruginosa Lung Infection (COPILOT) - Not yet recruiting
ongoing trials trial from other registries
Details- 2024
A randomised, double-blind, placebo controlled, two-part study to evaluate the efficacy, safety, tolerability and pharmacokinetics of a repeat dose of inhaled ETD001 in people with cystic fibrosis - Ongoing
ongoing trials trial from other registries
Details- 2024
A Phase 3, Open-label, and Rollover Study to Evaluate the Long-term Safety and Tolerability of Lumacaftor/Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation
ongoing trials trial from other registries
Details- 2023
Evaluation of the effects of curcumin-piperine in reducing Pseudomonas infection and improving clinical outcome in patients with cystic fibrosis - Pending
ongoing trials trial from other registries
Details- 2023
The randomized, double blind study phase III.b of the Comprehensive assessment of the musculoskeletal health in children with cystic fibrosis â on the search for means of improvement
ongoing trials trial from other registries
Details- 2022
Evaluation the effects of camel milk in spirometry parameters in over 6 yearâs children with Cystic Fibrosis lung disease - Recruiting
ongoing trials trial from other registries
Details- 2022
A Phase 3 Open-label Study Evaluating the Longterm Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects With Non-F508del CFTR Genotypes
ongoing trials trial from other registries
Details- 2021
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis
ongoing trials trial from other registries
Details- 2021
A Phase 3 Double-blind, Randomized, Placebo-controlled Study Evaluating the Efficacy and Safety of ELX/TEZ/IVA in Cystic Fibrosis Subjects 6 Years of Age and Older With a Non-F508del ELX/TEZ/IVA-responsive CFTR Mutation
ongoing trials trial from other registries
Details- 2021
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation
ongoing trials trial from other registries
Details- 2021